Email this article Xenobiotic response elements (XRE) from human CYP1A1 gene enhance the hTERT promoter activity
- Authors: Shepelev M.V.1, Kalinichenko S.V.1, Saakian E.K.1, Korobko I.V.1
-
Affiliations:
- Institute of Gene Biology of the Russian Academy of Sciences
- Issue: Vol 485, No 5 (2019)
- Pages: 634-637
- Section: Biochemistry, biophysics, molecular biology
- URL: https://journals.eco-vector.com/0869-5652/article/view/14321
- DOI: https://doi.org/10.31857/S0869-56524855634-637
- ID: 14321
Cite item
Full Text
Abstract
A hybrid 6XRE-hTERT promoter consisting of the hTERT tumor-specific promoter and six copies of the XRE element from the CYP1A1 human gene promoter was created. Using a human lung cancer cells as a model, we showed that XRE elements in the hybrid promoter greatly increase the activity of the hTERT promoter and ensure the reporter gene transcriptional activation in response to the treatment of the cells with the AhR ligand benzo(a)pyrene. However, similar effects were also observed in normal human bronchial epithelial cells HBEpC, which indicates the loss of the tumor-specific activity by the 6XRE-hTERT hybrid promoter. XRE elements can be used for nonspecific transcription enhancement but are unsuitable for the creation of tumor-specific promoters with enhanced activity.
About the authors
M. V. Shepelev
Institute of Gene Biology of the Russian Academy of Sciences
Author for correspondence.
Email: mshepelev@mail.ru
Russian Federation, 34/5, Vavilova street, Moscow, 119334
S. V. Kalinichenko
Institute of Gene Biology of the Russian Academy of Sciences
Email: mshepelev@mail.ru
Russian Federation, 34/5, Vavilova street, Moscow, 119334
E. K. Saakian
Institute of Gene Biology of the Russian Academy of Sciences
Email: mshepelev@mail.ru
Russian Federation, 34/5, Vavilova street, Moscow, 119334
I. V. Korobko
Institute of Gene Biology of the Russian Academy of Sciences
Email: mshepelev@mail.ru
Russian Federation, 34/5, Vavilova street, Moscow, 119334
References
- Das S.K., Menezes M. E., Bhatia S., Wang X. Y., Emdad L., Sarkar D., Fisher P. B. // J. Cell Physiol. 2015. V. 230. P. 259-271.
- Fujiwara T., Urata Y., Tanaka N. // Curr. Cancer Drug Targets. 2007. V. 7. P. 191-201.
- Wirth T., Zender L., Schulte B., Mund B., Plentz R., Rudolph K. L., Manns M., Kubicka S., Kuhnel F. // Cancer Res. 2003. V. 63. P. 3181-3188.
- Davis J.J., Wang L., Dong F., Zhang L., Guo W., Teraishi F., Xu K., Ji L., Fang B. // Cancer Gene Ther. 2006. V. 13. P. 720-723.
- Shepelev M.V., Kopantzev E. P., Vinogradova T. V., Sverdlov E. D., Korobko I. V. // Oncol. Lett. 2016. V. 12. P. 1204-1210.
- Калиниченко С.В., Шепелев M. В., Вихрева П. Н., Коробко И. В. // Acta Naturae. 2017. Т. 9. С. 66-73.
- Murray I.A., Patterson A. D., Perdew G. H. // Nat. Rev. Cancer. 2014. V. 14. P. 801-814.
- Li S., Pei X., Zhang W., Xie H. Q., Zhao B. // Int. J. Mol. Sci. 2014. V. 15. P. 6475-6487.
- Sarkar P., Shiizaki K., Yonemoto J., Sone H. // Int. J. Oncol. 2006. V. 28. P. 43-51.
Supplementary files
